From investigational product to active reference: evolution of oral sumatriptan efficacy versus placebo for the treatment of acute migraine episodes and potential impact in comparative analyses-Reference-Cited by-同舟云学术

From investigational product to active reference: evolution of oral sumatriptan efficacy versus placebo for the treatment of acute migraine episodes and potential impact in comparative analyses

Published:2019-01-01 Issue:1 Volume:7 Page:1603538
ISSN:2001-6689
Container-title:Journal of Market Access & Health Policy
language:en
Short-container-title:Journal of Market Access & Health Policy

Author:

Thokagevistk Katia¹,François Clément¹²,Brignone Mélanie³,Toumi Mondher¹²

Affiliation:

1. Health Economics and Outcomes Research, Creativ-Ceutical, Paris, France

2. Public Health Department- Research Unit, Aix-Marseille University, Marseille, France

3. Health Economics and Outcomes Research, Lundbeck SAS, Paris

Publisher

Informa UK Limited

Link

https://tandfonline.com/doi/pdf/10.1080/20016689.2019.1603538

Reference18 articles.

1. Can we well assess the relative efficacy and tolerability of a new drug versus others at the time of marketing authorization using mixed treatment comparisons? A detailed illustration with escitalopram

2. Evolution Of Tiotropium Efficacy Vs. Placebo Over Time For The Maintenance Therapy Of Chronic Obstructive Pulmonary Disease: From Investigational Product To Active Reference

3. Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1

4. European Medicines Agency. Brintellix. 2013 [cited 2013 Oct 24]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002717/WC500159447.pdf

5. Sumatriptan in the acute treatment of migraine